Observational Study to Evaluate the Simplified-STroke REhabilitation Assessment of Movement (S-STREAM) Scale in Subjects Who Have Experienced a Nonhemorrhagic Ischemic Stroke

NCT ID: NCT01496885

Last Updated: 2021-02-03

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

120 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-01-18

Study Completion Date

2013-05-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the utility of the S-STREAM as an instrument to assess motor function in subjects who have experienced a nonhemorrhagic ischemic stroke.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Nonhemorrhagic Ischemic Stroke Motor Function

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Nonhemorrhagic Ischemic Stroke

Subjects obtained within 24 to 48 hours of a nonhemorrhagic ischemic stroke

Observational study

Intervention Type OTHER

This was an observational study and no study drug was administered.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Observational study

This was an observational study and no study drug was administered.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female participants between 21 and 85 years, inclusive
* Participants had no prior history of stroke (unless the stroke was silent or not associated with a motor deficit) presented between 24 and 48 hours from onset with an acute stroke with clinical assessments and imaging studies (conducted as part of the standard of care procedures in stroke patients) indicating that the stroke was ischemic, with no secondary hemorrhage large enough to exert a mass effect that would contribute significantly to the neurological deficit (small punctate hemorrhages were permitted), in the vascular distribution of the middle cerebral artery and not classifiable as a lacunar stroke
* Participants understood and agreed to comply with the requirements of the study and they were willing to provide verbal/nonverbal informed consent indicating voluntary consent to participate in the study
* Participants were to have scored at least 16 on the Mini Mental Status Examination (MMSE) at screening. If the participant had an expressive aphasia and was unable to qualify based on the MMSE, the participant may have been evaluated with a language-modified form of the MMSE1 in conjunction with the investigator's clinical assessment that the participant was cognitively able to complete study procedures and stroke scales to determine eligibility. If the aphasia was too severe for the participant to complete the language-modified MMSE, the participant was excluded.
* Participants had to have a total score between 20 and 85, inclusive, on the S-STREAM administered between 24 and 48 hours after stroke onset

Exclusion Criteria

* History of previous stroke; uncontrolled severe hypertension; dementia; advanced Parkinson disease or other significant movement disorders; or other clinically significant diseases which, in the opinion of the investigator, would have jeopardized the safety of the participant or impacted the validity of the study results
* Development of hemodynamic instability following the stroke as manifested by a persistent post stroke systolic blood pressure less than 80 mm Hg (or was dependent on medications to maintain a systolic blood pressure greater than or equal to 80 mm Hg) or greater than 190 mm Hg at the time of screening
* Presence of significant global or receptive aphasia that would have interfered with the participant's ability to understand and comply with study procedures or complete stroke assessments
* Abnormal clinical laboratory values on routine clinical laboratory test values at screening including alanine transaminase or aspartate transaminase greater than or equal to 3 times the upper limit of normal, serum creatinine greater than or equal to 3.0 mg/dL, or hemoglobin less than or equal to 10 g/dL, or any other laboratory investigation deemed by the investigator to be indicative of a clinically significant illness that could have prevented the participant from complying with study procedures or impacted on the outcome of the stroke scales
* History of drug or alcohol abuse
* History of any surgery or presence of any medical condition that, in the judgment of the investigator, may have affected the validity of the study results
* Current participation in another clinical study involving administration of an investigational product or history of such participation within 30 days of screening
* Unable to complete baseline S-STREAM and NIHSS assessments within 48 hours of stroke onset
Minimum Eligible Age

21 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Daiichi Sankyo

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Global Clinical Leader

Role: STUDY_DIRECTOR

Daiichi Sankyo

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Newport Beach, California, United States

Site Status

Englewood, Colorado, United States

Site Status

Lawrenceville, Georgia, United States

Site Status

Chicago, Illinois, United States

Site Status

Des Moines, Iowa, United States

Site Status

Boston, Massachusetts, United States

Site Status

Springfield, Massachusetts, United States

Site Status

Worcester, Massachusetts, United States

Site Status

Detroit, Michigan, United States

Site Status

Edison, New Jersey, United States

Site Status

Brooklyn, New York, United States

Site Status

The Bronx, New York, United States

Site Status

Portland, Oregon, United States

Site Status

Hershey, Pennsylvania, United States

Site Status

Philadelphia, Pennsylvania, United States

Site Status

Philadelphia, Pennsylvania, United States

Site Status

Charleston, South Carolina, United States

Site Status

Chattanooga, Tennessee, United States

Site Status

Nashville, Tennessee, United States

Site Status

Norfolk, Virginia, United States

Site Status

Richmond, Virginia, United States

Site Status

Seattle, Washington, United States

Site Status

Calgary, Alberta, Canada

Site Status

Edmonton, Alberta, Canada

Site Status

Edmonton, Alberta, Canada

Site Status

Greenfield Park, Quebec, Canada

Site Status

Montreal, Quebec, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ASBI 801

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Multicenter Rehabilitation Study in Acute Stroke
NCT00849303 UNKNOWN PHASE2/PHASE3
Walking Study for Stroke Rehabilitation
NCT00428480 COMPLETED PHASE1